Apple Watch Blood Oxygen Monitoring Gets Major Breakthrough
The US International Trade Commission (ITC) has declined to review a prior ruling that found Apple's redesigned blood oxygen technology on the Apple Watch does not infringe Masimo's patents. The decision allows Apple to continue offering blood oxygen monitoring on the Apple Watch in the US using its redesigned system.
Apple has secured a significant victory in its dispute with Masimo over the blood oxygen feature on the Apple Watch. The US International Trade Commission (ITC) declined to review a prior ruling that found Apple's redesigned blood oxygen technology does not infringe Masimo's patents. The ITC's decision confirms that the redesigned products 'do not infringe the Asserted Patents, and therefore, they should not be excluded.' Apple redesigned the feature to collect data on the watch but process and display results on a paired iPhone. The decision allows Apple to continue offering blood oxygen monitoring in the US. Masimo still has legal options, including appealing the decision to the US Court of Appeals for the Federal Circuit.
This content was automatically generated and/or translated by AI. It may contain inaccuracies. Please refer to the original sources for verification.